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Molecular diagnostic tests, based on the detection and identiﬁcation of nucleic acids in human biological samples, are increasingly employed in the
diagnosis of infectious diseases and may be of future beneﬁt to CF microbiology services. Our growing understanding of the complex polymicrobial
nature of CF airway infection has highlighted current and likely future shortcomings in standard diagnostic practices. Failure to detect fastidious or slow
growing microbes and misidentiﬁcation of newly emerging pathogens could potentially be addressed using culture-independent molecular technologies
with high target speciﬁcity. This review considers existing molecular diagnostic tests in the context of the key requirements for an envisaged CF
microbiology focussed assay. The issues of assay speed, throughput, detection of multiple pathogens, data interpretation and antimicrobial susceptibility
testing are discussed.
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Over recent years nucleic acid based technologies have been
increasingly exploited in human health, both in the analysis of
human genes and in the detection and analysis of pathogenic
micro-organisms. Assays targeting human genes and their
expression can be used in screening to identify people at
increased risk of disease, in the diagnosis of hereditary conditions,
for detection of disease associated biomarkers and in predicting or
monitoring response to treatment. Microbial nucleic acids can be
targeted for the diagnosis of infectious diseases, to identify
epidemic strains or pathogenicity traits, and for predicting or
monitoring response to treatment. Molecular tests are promoted
within clinical diagnostics due to their potential for rapid delivery
of results, high sample throughput, accuracy, sensitivity and
reproducibility. The focus of this review is the potential for using
molecular tests in routine clinical practice to detect and identify
respiratory pathogens associated with cystic fibrosis (CF).2. CF lung health
Lung infection is the major cause of morbidity and mortality
in CF patients [1] with improvements in antibiotic therapy
contributing towards increased life expectancy. An improved
ability to determine the presence of pathogens would allow
more directed treatment, and may further improve outcomes for
patients.
In the context of routine patient care and treatment of an
infective exacerbation, the detection and identification of CF
pathogens through diagnostic microbiology has proved beneficial
in several ways. Monitoring people with CF from infancy
promotes early discovery of newly acquired infections, thereby
increasing the likelihood of eradication though timely treatment.
Early eradication of Pseudomonas aeruginosa is recognised as
contributing to better patient outcomes and reduced treatment
costs [2,3]. Furthermore, it provides direct evidence of a response
to antibiotic treatment where the goal and expectation is to
completely clear an infection. This may have consequences
clinically as failure to eradicate P. aeruginosa infection in
children is linked to a higher risk of subsequent exacerbation and
may be indicative of emerging chronic infection [4]. Routine
outpatient clinics are also commonly segregated according to
infection type to limit cross-infection between patient cohorts
colonised with Burkholderia cepacia complex (Bcc), meticillin-resistant Staphylococcus aureus (MRSA) and P. aeruginosa
[5,6]. Infection type also has implications for the organisation of
inpatient care, such as admission to separate wards and the
provision of individual rooms preferably with en suite facilities
[5,6].
Regular microbiological surveillance to detect CF airway
pathogens is recommended as best practice in CF patient care
[5–7]. Depending on disease severity, the Cystic Fibrosis Trust
and European Cystic Fibrosis Society (ECFS) advocate routine
outpatient check-ups 4 to 6 times per year for clinically stable
patients [5,6]. Additionally, respiratory samples are analysed
following diagnosis of pulmonary exacerbation in order to guide
choice of antibiotic therapy. Exacerbations are usually treatedwith
intravenous antibiotics in a hospital setting or with homecare
support [6,8] and at least 10–14 days of treatment has been
recommended by the Cystic Fibrosis Trust [9]. Weekly microbi-
ology culture is recommended by the ECFS for the duration of
treatment [6].3. Which microbes are clinically relevant in CF lung disease?
3.1. Historically recognised pathogens
Traditionally, the clinical impact of CF lung infections was
attributed to the role played by a small number of pathogens,
namely P. aeruginosa,Haemophilus influenzae, S. aureus and B.
cepacia. Whilst these bacterial species have been associated with
increased morbidity and mortality [10], their early identification
as CF pathogens may have arisen, at least in part, from the
relative ease with which they were detected by the culture
practices employed at the time. Conversely, the same practices
may not have detected more fastidious, anaerobic or slow
growing pathogens. In recent years, the complexity of CF lung
infection has been increasingly recognised. Conventional
CF-related bacteria (P. aeruginosa, H. influenzae, S. aureus,
B. cepacia, Stenotrophomonas maltophilia and Achromobacter
xylosoxidans) have been found to be absent from the sputum of
17% of patients with a pulmonary exacerbation [11], with
enhanced culture [12–14] and molecular techniques identifying
the presence of an unexpectedly diverse range of previously
undetected bacteria, fungi and viruses. The role of many of these
newly detected species in CF lung disease is unclear, with studies
on-going to determine their pathogenicity and clinical relevance.
The primary infectious agents, including bacteria, fungi and
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recorded in Table 1.
3.2. Recently detected diversity in the CF lung
Technological developments in the field of molecular
microbiology have provided an opportunity to reassess the list
of microbes traditionally associated with CF lung infections. In
recent years, a range of DNA based techniques have exploited
the 16S ribosomal RNA gene sequence for the detection and
identification of bacterial species or taxa. Methodologies
include terminal restriction fragment length polymorphism
(T-RFLP) [17], phylogenetic hybridisation microarrays [18],
clone library sequencing [19] and next generation sequencing
[14,20,21]. Initially, microbiota studies tended to be qualitative,
describing the wide diversity of bacteria detected. However,
more recently quantitative pyrosequencing data have been
published. The largest longitudinal study to date followed 6
patients for 8–9 years, with 13–20 samples collected from each
[22], whilst the largest cross-sectional study analysed a single
sample from each of 35 patients [23]. A third study analysed 63
sputum samples from 23 patients to monitor the effect of
antibiotic treatment on community composition [24], whilst
two other investigations analysed 2 samples from each of 4
patients [25] and 1 sample from each of 3 patients [20],
respectively. Bacterial genera, detected at N1% abundance in at
least one CF patient in these studies, are recorded in Table 2.
Although high abundance of a species or genus does not
necessarily signify pathogenicity, it identifies the potential forTable 1
Bacteria, fungi and viruses considered clinically relevant in CF lung infection.
Infectious agents a Cystic Fibrosis
Trust [15]
ECFS
[6]
Hauser et
al. [16]
Staphylococcus aureus ✓ ✓ ✓
Haemophilus influenzae ✓ ✓ ✓
Streptococcus pneumoniae ✓ ✓
Pseudomonas aeruginosa ✓ ✓ ✓
Burkholderia cepacia complex ✓ ✓ ✓
Stenotrophomonas maltophilia ✓ ✓ ✓
Achromobacter xylosoxidans ✓ ✓ ✓
Non-tuberculous mycobacteria ✓ ✓ ✓
Other Burkholderia spp. ✓
Ralstonia spp. ✓ ✓
Pandoraea spp. / P. apista ✓ ✓ ✓
Anaerobic bacteria ✓ ✓
Streptococcus spp. ✓ ✓
Moraxella catarrhalis ✓
Inquilinus limosus ✓
Aspergillus spp. ✓ ✓ ✓
Scedosporium apiospermum ✓
Wangiella dermatitidis ✓
Influenza virus ✓ ✓ ✓
Respiratory syncytial virus ✓ ✓
Parainfluenza virus ✓
Adenovirus ✓
Rhinovirus ✓
Metapneumovirus ✓
Respiratory viruses ✓
a As described in the references cited.clinical impact and may indicate an increased health risk if the
species/genera were found to be harmful. The majority of
genera reported at N1% abundance belong to the Firmicutes,
Proteobacteria, Actinobacteria and Bacteroidetes phyla, with
Pseudomonas, Streptococcus, Prevotella and Rothia genera
being detected at N1% in at least one patient in all five studies.
As these investigations vary greatly in their design and scope
and involve heterogeneous patient groups, more data is
required to give an accurate picture of the typical relative
abundances of bacteria found in the CF lung. Furthermore,
increasing evidence points to a reduction in diversity as lung
disease progresses [18,22,26], thereby linking microbial com-
munity composition to clinical status. Thus, it may be more
accurate to consider different microbial community profiles as
typical at specific stages of patient health.
3.3. Clinical relevance of newly detected species
The detection of bacterial species in respiratory samples does
not necessarily mean that they have a clinically important role in
infection and determining their impact poses a major challenge to
both researchers and clinicians. Ultimately a species can only be
deemed clinically relevant if it is shown that clinical signs and
symptoms are worse in patients where it is present as compared to
patients where it is absent. However, a number of key factors can
help predict the potential clinical impact of the different genera
detected. These include—
(a) Are the organisms pathogenic in other infections?
(b) Do they possess virulence genes or exhibit virulence in in
vitro or animal infection models?
(c) Are they present in significant numbers?
(d) Do they enhance or suppress the pathogenicity of other
bacteria?
(e) Are they colonising or transient?
For example, no data currently exists demonstrating the
clinical impact of any of the anaerobic genera found in the CF
lung; however, some of the species detected include known oral
pathogens which possess virulence genes, have demonstrated
virulence in vitro or in a mouse lung infection model, are
abundant and prevalent in the CF lung, and contribute to the core
microbiota [12,14,20,27]. Additionally, 94% CF patients were
found to have antibodies against two immunoreactive antigens of
Prevotella intermedia [27]. Thus, application of the above criteria
suggests that some anaerobic species may be significant in CF
lung disease and warrant further investigation.
Antimicrobial therapy is generally targeted at new infections in
non-colonised patients and the predominant pathogen in chron-
ically colonised patients. Currently, the presence or acquisition of
additional infections by a chronically colonised patient is unlikely
to alter treatment as chronic infections tend to be treated with
broad spectrum antibiotics targeting the predominant pathogen.
These antibiotics are thought to have some effect on the
majority of conventionally recognised CF pathogens [28].
Nevertheless, treatment may sometimes be used directly against
existing, non-predominant pathogens, such as to target increases
Table 2
Bacterial genera reported as detected at N1% abundance in the lungs of at least
one CF patient.
Bacterial phylum/genus Zhao et
al. [22]
(n=126)
Fodor et
al. [24]
(n=63)
Filkins et
al. [23]
(n=35)
Delhaes et
al. [25]
(n=8)
Guss et
al. [20]
(n=3)
Actinobacteria
Actinomyces ✓ ✓ ✓ ✓
Atopobium ✓ ✓
Blastococcus ✓
Bogoriella ✓
Corynebacterium ✓ ✓
Curtobacterium ✓
Micromonospora ✓
Rothia ✓ ✓ ✓ ✓ ✓
Scardovia ✓
Bacteroidetes
Bacteroides ✓
Capnocytophaga ✓ ✓
Cloacibacterium ✓
Porphyromonas ✓ ✓ ✓ ✓
Prevotella ✓ ✓ ✓ ✓ ✓
Sphingobacterium ✓
Deinococcus–Thermus
Thermus ✓
Firmicutes
Abiotrophia ✓ ✓
Catonella ✓ ✓
Enterococcus ✓
Gemella ✓ ✓ ✓ ✓
Granulicatella ✓ ✓ ✓
Johnsonella ✓ ✓
Lactobacillus ✓ ✓
Megasphaera ✓ ✓
Mogibacterium ✓
Moryella ✓
Oribacterium ✓ ✓ ✓
Paenibacillus ✓
Parvimonas ✓ ✓ ✓
Planomicrobium ✓
Solobacterium ✓ ✓
Staphylococcus ✓ ✓ ✓ ✓
Streptococcus ✓ ✓ ✓ ✓ ✓
Veillonella ✓ ✓ ✓ ✓
Fusobacteria
Fusobacterium ✓ ✓ ✓ ✓
Leptotrichia ✓ ✓
Proteobacteria
Achromobacter ✓ ✓
Acinetobacter ✓
Actinobacillus ✓
Aggregatibacter ✓
Bradyrhizobium ✓
Burkholderia ✓
Campylobacter ✓
Chryseomonas
Devosia ✓
Dickeya ✓
Eikenella ✓
Haemophilus ✓ ✓ ✓ ✓
Moraxella ✓
Neisseria ✓ ✓ ✓ ✓
Pasteurella ✓
Pseudomonas ✓ ✓ ✓ ✓ ✓
Sphingomonas ✓
Stenotrophomonas ✓ ✓
Table 2 (continued)
Bacterial phylum/genus Zhao et
al. [22]
(n=126)
Fodor et
al. [24]
(n=63)
Filkins et
al. [23]
(n=35)
Delhaes et
al. [25]
(n=8)
Guss et
al. [20]
(n=3)
Tenericutes
Mycoplasma ✓ ✓
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pseudomonal antibiotics [29,30]. Nontuberculous mycobacteria
may also warrant specific treatment [31]. As more knowledge is
gained about the polymicrobial nature of CF infection, future
treatment practices may change. Considerations might include
prescribing antibiotics effective against anaerobes [13] or targeting
bacteria which can increase the pathogenicity of the principal
pathogen [32–35].
4. CF diagnostic microbiology
4.1. Current practice
In order to facilitate appropriate targeted treatment of infections
by those species deemed pathogenic, there must first be effective
strategies for their detection and identification. Current practice for
diagnosis of CF infection depends on the microbial culture of a
patient's sputum, cough swab, oropharyngeal swab or bronchoal-
veolar lavage (BAL) sample. The Cystic Fibrosis Trust guidelines
[15] recommend the use of several selective and non-selective
agars, and occasionally liquid culture, to maximise detection of
pathogens commonly implicated in CF infections. Suspected
pathogens are then isolated and subsequent identification is
informed by a combination of visual characteristics, biochemistry
tests, commercial phenotypic-based kits and instrumentation, with
PCR amplification/sequencing of genes specific to individual
pathogens and Matrix-Assisted Laser Desorption Ionisation-Time
of Flight mass spectrometry (MALDI-TOF MS) also used. In
some cases, consultation with a specialist reference laboratory may
be required. In vitro antibiotic susceptibilities for the predominant
pathogen are also typically determined.
4.2. Limitations
Standard diagnostic microbiology takes several days for a
definitive report and requires highly specialised knowledge and
experience gained over many years [6]. The challenge of
applying such techniques effectively is highlighted by two recent
quality assessment trials that observed significant shortcomings
in laboratories across Europe providing microbiological services
to large CF centres [36]. The trials assessed 31 laboratories in
2007 and 37 in 2008 for identification of microbial species from
respiratory specimens, either as single isolates or in mixtures,
with the same nine formulations being sent to each laboratory.
Common pathogens such as P. aeruginosa, S. aureus and a
S. aureus small colony variant, were correctly identified,
whilst uncommon or newly emerging pathogens were frequently
not detected or misidentified. For example, A. xylosoxidans and
Pandoraea pnomenusa received incomplete/wrong identifications
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respectively, in 2007, and Inquilinus limosus by 14/37 (38%)
laboratories in 2008. In addition to the unexpected deficits
uncovered by these trials, the authors suggest that as the
participating laboratories had been specifically selected for
their size and research activity, it might be expected that
other smaller laboratories would have performed less well.
Some identification failures may have been due to difficul-
ties associated with commonly used phenotypic identifica-
tion systems, such as the low biochemical reactivity of the
bacteria tested, loss of its characteristic phenotypes during
chronic colonisation or its absence from the commercial
database [37,38]. As the number of species recognised as
potentially pathogenic in this context increases, routine diagnostic
CF microbiology is likely to become even more complex. This
would present an increased challenge both with respect to detection
by culture and subsequent correct identification.
4.2.1. Detection by culture
Pathogen detection through conventional culture is compli-
cated by the problem of slow growing or fastidious microbes
being overgrown by more abundant, faster growing organisms,
and by a lack of routine culture conditions appropriate for the
growth of some emerging pathogens. Both issues may result in
clinically relevant microbes being overlooked. Whilst more
extensive culture methods using multiple combinations of special
media and growth conditions can detect the majority of CF
bacteria identified by molecular methods in CF sputum [14], this
approach is not practical for routine clinical laboratories.
Continuing reliance on culture-based methods would necessitate
the expansion of existing clinical culture procedures to include
more laborious and potentially more demanding practices to
enable reproducible detection of newly emergent pathogens. In
the case of anaerobic bacteria, where clinical relevance can be
demonstrated, the difficulties associated with effective anaerobic
culture would have to be addressed. This was highlighted by a
recent study evaluating culture protocols for pathogen identifica-
tion in BAL samples from 12 CF patients [39]. The authors
reported that anaerobic cultures were either negative (42%) or
overgrown with aerobes (58%) and therefore diagnostically
ineffective, yet other culture-based studies have been able to
detect and isolate anaerobes from the majority of sputum samples
[12,14,40]. Additionally, the incidence and abundance of
potential fungal pathogens in CF sputum have been found to
vary between geographical regions, most likely due to a lack of
appropriate standardised culture practices [41]. Similar inconsis-
tencies between 180 North American CF sites had also been
reported for the detection of traditional CF bacterial pathogens
prior to standardisation of clinical laboratory practices [42].
Furthermore, although viruses are recognised as contributing to
patient poor health and are linked to pulmonary exacerbations
[43], sputum samples are not routinely screened for their
presence.
4.2.2. Species identification
Whilst fastidious growth and limited culture practices may
contribute to failed detection of CF pathogens, misidentificationand incomplete identification are also common [36]. In an
investigation of molecular methods for the detection and
identification of bacteria in CF sputum, conventional phenotypic
methods incorrectly identified 5 out of 20 known pathogens
isolated from children with CF and 3 out of 13 bacteria from adult
patients [44]. Recently, MALDI-TOFMS has been applied to the
identification of bacterial isolates by matching their protein mass
spectra against a commercial library of pre-determined reference
spectra. Two of these systems, the Bruker BioTyper and
bioMérieux's VITEK® MS Matrix-Assisted Laser Desorption
Ionisation-Time of Flight Mass Spectrometry System, have been
evaluated against biochemical or molecular reference methods for
identification of nonfermenting gram-negative bacilli isolated
from CF patient sputa [45]. Both instruments performed well,
with the Bruker Biotyper and Vitek MS agreeing with reference
identifications at the combined species/complex/genus level for
194/200 (97%) and 179/200 (89.5%) isolates, respectively. Other
trials also demonstrated the use of MALDI-TOF MS for
definitive identification of Bcc isolates to the species level
[46–48]. The Bruker instrument has been additionally tested
directly on CF sputum for pathogen identification without prior
culture, but was less suitable for this application [49]. This means
that although MALDI-TOF MS can improve the identification of
bacteria, its sensitivity is currently limited by the efficiency of
routine sample culturing and pathogen isolation. Nevertheless,
MALDI-TOF MS is increasingly being employed in clinical
diagnostic laboratories and has distinct advantages over tradi-
tional phenotypic identification methods. A recent study found
that 40/47 (85%) isolates from CF patients were identified by
MALDI-TOF MS within 48 h of sample incubation compared to
only 16/47 (34%) by conventional methods [46]. In particular, 15/
21 (72%) of P. aeruginosa isolates were identified by day 2 and
17/19 (89%) of S. aureus isolates by day 1 with MALDI-TOF
MS. In contrast, no P. aeruginosa isolates and 13/19 (68%) S.
aureus isolates were identified by day 2 using conventional
methods [46]. The authors concluded that adoption of this
technology would reduce time to result reporting to the clinical
care team and ultimately lead to improved patient outcomes.
Additionally, switching to MALDI-TOF MS has been observed
to be cheaper for routine bacterial identification [50].
4.2.3. In vitro antibiotic susceptibility
In addition to reporting on the presence of clinically important
bacterial species, conventional diagnostic microbiology also
provides information on the antibiotic susceptibility of isolates.
This information is generally used in guiding therapy choice.
However, these tests are not reproducible and are poorly
predictive of clinical outcome in the management of pulmonary
exacerbations caused by P. aeruginosa in both adult [51] and
paediatric [52] CF patients. Furthermore, in a recent retrospective
review of 452 pulmonary exacerbations occurring in our
centre over a 4 year period in patients chronically infected with
P. aeruginosa, 57% of pulmonary exacerbations were successful-
ly treated with regimens containing antibiotics which were not
deemed active against the cultured bacteria, as determined by in
vitro susceptibility testing [53]. This lack of concordance between
in vitro tests and clinical outcomesmay be as a result of standard in
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microbial community or environmental conditions found in the
CF lung. Relevant issues include the inherent phenotypic diversity
and instability within a chronically infecting P. aeruginosa
population, biofilm growth, anaerobic/microaerophilic conditions,
niche-specific nutrition and metabolism, and potential inter-
species interactions [54–58]. Furthermore, attempts to develop
more clinically relevant susceptibility tests through combination
[59,60] or biofilm [56,61–63] directed testing have shown no
consistent improvement in clinical or bacteriological outcome.
5. Molecular diagnosis of CF lung pathogens
5.1. Molecular diagnosis of infectious disease
Manymolecular diagnostic methods do not require the growth
and isolation of microorganisms, instead relying on the detection
of target nucleic acids. There are three major approaches to
microbial identification using nucleic acids extracted from
clinical samples. The first uses sequence specific hybridisation
of custom-designed primers and/or probes to detect the DNA or
RNA of individual microbial targets, generally through PCR
amplification. A range of hybridisation-based assays of varying
design are already used in routine clinical practice for infectious
disease diagnosis. The other two approaches, based on sequenc-
ing and PCR-mass spectrometry, are recently emerging technol-
ogies not yet adopted into routine clinical practice. Exceptions to
this are two sequencing based assays, ViroSeq™ HIV-1
Genotyping System (Celera Diagnostics) and TruGene™ HIV-1
Genotyping and Open Gene DNA Sequencing System (Siemens
Healthcare Diagnostics), which have been developed for HIV
drug resistance testing [64].
Regulatory legislation governs whether a commercial diag-
nostic test can be marketed as an in vitro diagnostic for clinical
use. For sales within Europe or the USA this entails CE marking
or FDA approval, respectively, whilst regulation outside these
regions varies nationally [65]. Approval requires evaluation of
assay sensitivity and specificity, as well as proof of manufacturing
consistency and the stability of test reagents, so guaranteeing
reliability within the performance parameters claimed. To date,
the FDA has approved just over 100 molecular tests from 27
manufacturers for the clinical detection and identification of
bacterial, viral and fungal infections in various human biological
samples based on hybridisation technologies [64]. Central to the
majority of tests, is the amplification of a nucleic acid sequence
unique to the target pathogen, with the amplified region
(amplicon) being detected via reporter molecules either after or
during the amplification step. The polymerase chain reaction
(PCR) was the first and is still the most commonly employed
method for amplification of a DNA target. It can be adapted for
RNA targets, such as some viral genomes, by adding an initial
reverse transcription step, known as RT-PCR. More recently,
alternative amplification techniques have been developed and
adopted into commercial molecular diagnostics due to their lower
running costs and reduced reaction times [66–68]. Real-time PCR
combines target amplification and detection in a single process.
Approximately half of the manufacturers of FDA approved testsfor the detection of infectious agents employ real-time PCR
technology in their assays [64]. Alternatively, in tests where target
amplification and detection are separate, detection methods
involve binding to target-specific probes or use of a secondary
nested target-specific PCR.5.2. Clinical requirements and considerations for a CF
microbiology test
In order for a future molecular diagnostic assay to improve
upon current CF microbiology practice, the defining require-
ments of the assay would be efficient detection and accurate
identification of multiple CF-associated pathogens, directly from
a patient sample, in a clinically beneficial timescale. Initially, the
minimum specification should include the pathogens listed by
expert bodies as clinically relevant (Table 1). However, assay
flexibility would be required to allow future inclusion of other
species as deemed clinically relevant. Additional desirable
features not fully satisfied by current methodology may include
the capability for quantitative reporting and antibiotic suscepti-
bility measurements more predictive of in vivo response. Full
automation within a contained environment would also be highly
desirable as this would improve assay robustness by reducing the
risk of operator error or sample contamination.
A number of considerations are applicable to any potential
molecular diagnostic format to ensure delivery of good quality
data which is truly representative of the in vivomicrobiota. These
issues have been discussed comprehensively by Rogers and
Bruce in their review addressing the clinical application of
next-generation sequencing to the human microbiome, including
the detection of CF pathogens [69]. In particular, the authors
emphasise that careful consideration should be given to (a) repeat
sampling if maximum coverage of community diversity is
required, (b) exclusion of extracellular DNA or DNA from dead
cells from quantitativemeasurements, (c) development of a robust
DNA extraction protocol equally efficient for all species present,
and (d) exclusion of PCR contaminants, including exogenous
DNA in commercial reagents.5.3. Currently approved tests
Some FDA approved tests already exist which detect
pathogens relevant to CF, such as Streptococcus spp., S. aureus,
MRSA, H. influenzae, influenza viruses A & B and respiratory
syncytial viruses A & B [64]. However, the majority of important
CF airway pathogens are overlooked, includingP. aeruginosa and
Bcc. Thus, none of the currently available tests, or combinations
of tests, is adequate for comprehensive CF microbiology for
routine clinical purposes. Nevertheless, the technologies involved
in existing tests and perhaps some of the existing tests themselves,
could be adapted and validated for the detection of CF lung
pathogens. The key aspects of molecular assay design most
significant to clinical CF microbiology (multiplexing, throughput
and automation, and data interpretation) and recent developments
in molecular approaches to antimicrobial susceptibility testing are
described below.
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5.4.1. Multiplexing
As outlined above, CF respiratory samples may contain more
than one pathogen of interest. To detect all clinically relevant
pathogens, future molecular CF microbiology assays would have
to detect a number of separate targets. One solution would be to
run multiple single target tests consecutively or in parallel,
delaying the speed of reporting or limiting sample throughput,
respectively. Multiple reactions would also increase costs and
require larger sample volumes. Alternatively, multiplexing could
be used to combine multiple distinct tests in a single assay and
allow the simultaneous detection and identification of each
individual target present in a mixture. To date, six manufacturers
sell FDA approved molecular diagnostic tests for infectious
diseases which multiplex the detection of more than 3 targets.
Half of these tests use real-time PCR/RT-PCR to multiplex 4 or 5
targets. The other three manufacturers employ highlymultiplexed
PCR or RT-PCR for amplification of 7–20 targets and differ in
their modes of detection and identification. If detection and
identification of all the pathogens listed in Table 1 are required
for comprehensive diagnostic CF microbiology, a single highly
multiplexed assay would be preferable to maximise throughput
whilst minimising time-to-result.
5.4.2. Throughput and automation
One of the key benefits of molecular diagnostics is their
suitability for automation, with clear potential benefits in terms of
assay speed and sample throughput, and requiring minimal
operator input. In practice, automation tends to be balanced
against flexibility and instrument/running costs. The throughput
of a test, i.e. the number of results generated within a defined time
period, is governed by three parameters— the duration of a single
test, the degree of target multiplexing per test (the number of tests
that can be run in a single reaction), and the number of samples
which can be tested in parallel, either as a batch or staggered at
intervals. The priorities and throughput requirements of labora-
tories supplying diagnostic CF microbiology services would
drive the degree of automation designed into a potential
molecular CF microbiology diagnostic assay. Existing systems
already FDA approved for diagnosis of other specified infectious
diseases provide examples of automation strategies for multiplexed
testing which could be applicable to CF. These include fully
automated systems that operate independently sample-to-result,
and semi-automated systems that frequently divide the workflow
of a test into sample preparation including DNA extraction, assay
set-up, the assay itself and data analysis/results reporting [64]. Each
of these steps can be automated separately or performed manually,
and typically manual intervention is required between steps.
Examples of instrumentation approved by the FDA for defined
purposes are provided in Table 3. When compared with those
which are fully automated, semi-automated assays tend to have an
increased overall test run time so making larger batch size and/or
high multiplexing important for maximising throughput. More-
over, semi-automated assays may require significant input from
skilled technical staff both for the test procedure and for data
interpretation.As already stated, there are currently no FDA approved
molecular diagnostic assays suitable for complete CF microbiol-
ogy analysis. However, several fully- or semi-automated
instruments capable of multiplexed testing have been FDA-
approved for the diagnosis of respiratory pathogens from sputum
samples. This indicates that suitable technologies already exist
which could be transferable to CF microbiology if appropriate
assays were developed. In order to illustrate the potential of these
technologies, the sample throughput rates and performance
parameters for the existing multiplexed respiratory pathogen
assays currently FDA approved for clinical in vitro diagnostic use
are recorded in Table 4. All of the fully automated systems listed
test single samples independently in completely closed systems
with rapid time-to-results capabilities requiring less than 5 minutes
of hands-on time per sample. Higher throughput can be achieved
for the fully automated systems by using several stand-alone
instruments or employing a modular setup where one central
controller can run numerous assays independently in individual
assay units.
5.4.3. Data interpretation
Current CF microbiology services inform the clinician of
CF-associated pathogens detected in a sample and can to some
extent provide semi-quantitative information in terms of relative
abundance of the dominant pathogens. In order for a future
molecular CF microbiology assay to be valuable clinically, the
data gathered must similarly be interpreted and compiled into an
actionable report. For the majority of FDA approved molecular
assays, the output is qualitative in that target presence or absence
is reported without indicating how much target is present.
Research has shown that molecular assays employing target
specific amplification are frequently more sensitive than culture
[70]. This, combined with removal of the species bias introduced
by standard growth conditions, would be expected to enable
molecular reporting of microbes ordinarily overlooked by current
practices. Whilst advantageous for patient health when enabling
the earlier detection of pathogens of high clinical impact such as
P. aeruginosa, the value of increased sensitivity might be more
contentious if it resulted in the detection of a pathogen present at a
constant level that may be too low to affect patient health. As yet,
no minimum threshold levels associated with worse patient
outcomes have been established for the majority of pathogens.
Thus, the data output from any future molecular CFmicrobiology
assays might initially be difficult to interpret until clinically
significant thresholds are established and assay sensitivities are
adjusted appropriately. It should be noted that the lack of
definitive thresholds also applies to current culture-dependent
methods and that the clinical significance of bacteria detected are
usually judged subjectively by clinical microbiologists.
The availability of quantitative molecular reporting could be
beneficial, particularly to indicate response to treatment of a
chronic infection. However, this technology has not yet been
widely adopted into infectious disease diagnosis and the only
tests currently FDA approved are quantitative real-time PCR
assays for hepatitis B & C viruses and human immunodefi-
ciency virus, manufactured by Abbott, bioMérieux, Roche and
Siemens [64]. Interestingly, Seegene recently launched their
Table 3
Examples of instrumentation approved by the FDA for specified purposes.
Instrument Manufacturer Function(s) Product website
BD MAXTM System BD Diagnostics–
GeneOhm
Fully automated http://www.bd.com/geneohm/english/products/max/
GeneXpertTM Real-time
PCR System
Cepheid Fully automated http://www.cepheid.com/systems-and-software/genexpert-system
TIGRIS® DTS System Gen-Probe Fully automated http://www.gen-probe.com/products-services/tigris-dts-system
FilmArray System Idaho Technology Fully automated http://www.biofiredx.com/FilmArray/
Verigene® System Nanosphere Fully automated http://www.nanosphere.us/product/reader-and-processor-sp
MagNA Pure Systems Roche Nucleic acid extraction http://www.roche.com/products/product-details.htm?type=product&id=67
NucliSENS® easyMAG®
System
bioMérieux Nucleic acid extraction http://www.biomerieux-diagnostics.com/servlet/srt/bio/clinical-diagnostics/dynPage?
doc=CNL_PRD_CPL_G_PRD_CLN_70
QIAsymphony AS Qiagen Assay set-up http://www.qiagen.com/products/qiasymphonysp.aspx
m2000sp System Abbott Molecular Nucleic acid extraction
& assay set-up
http://www.abbottmolecular.com/us/products/instrumentation-automation/
realtime-pcr/m2000-sp-rt.html
LX100/200 Luminex Molecular
Diagnostics
Assay http://www.luminexcorp.com/Products/Instruments/Luminex100200/
SmartCyclerTM Real-time
PCR System
Cepheid Assay http://www.cepheid.com/systems-and-software/smartcycler-system
m2000rt System Abbott Molecular Assay http://www.abbottmolecular.com/us/products/instrumentation-automation/
realtime-pcr/m2000-sp-rt.html
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quantitative results in real-time for up to 28 targets in a single
multiplexed reaction [71]. Among their planned assays is the
QuantPlex™ RV-16 Assay, aimed at detecting, differentiating
and quantifying 21 respiratory viral pathogens associated with
upper respiratory disease. If successful, this technology might
in the future provide a useful basis for semi-quantitative
molecular CF microbiology testing.5.4.4. Antibiotic susceptibility
Whilst antibiotic susceptibility testing is typically practiced to
guide choice of therapy [72], and is recommended by the Cystic
Fibrosis Trust for early and intermittent P. aeruginosa isolates
[15] and by the ECFS for determining the susceptibility of
resistant pathogens to unusual antibiotics [6], its usefulness has
been questioned [51,52]. However, if culture-independent assays
are to replace conventional diagnostic microbiology, providing
equivalent information represents a significant challenge.Table 4
Comparison of throughput and performance for multiplex respiratory pathogen assa
Test (manufacturer) Multiplexing
FilmArray Respiratory Panel b (Idaho Technology) 17 viral & 3 bacterial tar
Verigene® Respiratory Virus Plus Test b (Nanosphere) 7 viral targets d
Xpert™ Flu b (Cepheid) 3 viral targets e
xTAG Respiratory Viral Panel FAST (Luminex) 8 viral targets f
a The highest and lowest sensitivities and specificities for an individual target wit
b Fully automated test.
c Adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus
A subtype H3, influenza A subtype H1 2009, influenza B, parainfluenza virus 1, parainf
respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae and Myco
d Influenza A, influenza B, respiratory syncytial virus A, respiratory syncytial virus B,
H1.
e Influenza A, influenza B and influenza A subtype 2009 H1N1.
f Influenza A, influenza A subtype H1, influenza A subtype H3, influenza B, respAntibiotic resistance is common in CF pathogens, including
the dominant pathogen P. aeruginosa. This resistance can be
intrinsic to the bacteria or develop by means of spontaneous
mutation or horizontal gene transfer, and manifests through a
number of mechanisms including reduced outer membrane
permeability, active efflux from the cell, target alteration to
prevent binding, and enzymatic inactivation of the drug molecule
[73]. The presence or absence of resistance genes relevant to CF
could be determined molecularly through target specific ampli-
fication. Examples of the use of this technology in current FDA
approved assays include the detection of vancomycin resistance
gene vanA, and mecA which confers meticillin resistance in
MRSA [64]. Conversely, the detection of gene mutations
conveying resistance to a CF pathogen would be more
complicated. The only examples of current FDA approved assays
capable of detecting drug resistance acquired through gene
mutation employ sequencing technologies.
If in vitro antibiotic susceptibility testing of CF pathogens
continues to be required, detection of specific resistance genesys FDA cleared for clinical in vitro diagnostic use.
Samples per run Run time Sensitivity (%) a Specificity (%) a
gets c 1 1 h 87.4–100 (95.9) 89.1–100 (98.9)
1 2.5 h 99.1–100 (99.7) 99.9–100 (100)
1 1 h 99.4–100 (99.8) 99.3–100 (99.8)
≤96 5 h 85.7–97.2 (93.8) 92.5–99.3 (97.4)
hin each test are recorded followed by the mean for all test targets in brackets.
OC43, human metapneumovirus, influenza A, influenza A subtype H1, influenza
luenza virus 2, parainfluenza virus 3, parainfluenza virus 4, rhinovirus/enterovirus,
plasma pneumoniae.
influenza A subtype 2009H1N1, influenza A subtype H3 and influenza A subtype
iratory syncytial virus, human metapneumovirus, rhinovirus and adenovirus.
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modes of resistance exploited. Additionally, gene sequencing
may be impractical due to the number of genes potentially
involved and their additive effects [74]. An alternative approach
could be based on a semi-molecular method which has been
described in several formats for the antibiotic susceptibility
testing of blood cultures [75–77], Bacillus anthracis [78] and
bacteria commonly isolated in clinical laboratories, including S.
aureus,H. influenza and P. aeruginosa [79]. In essence, bacterial
isolates or blood cultures are grown with and without antibiotics
and quantitative real-time PCR detection of 16S rRNA genes or
other targets used to measure differences in growth, so indicating
antibiotic susceptibility or resistance. This methodology has been
reported as accurate in the scenarios tested and generally more
rapid than conventional testing methods.
5.5. Emerging technologies for infectious disease diagnosis
The considerable advances in next-generation sequencing
technologies over the past few years have greatly enhanced the
quantity and speed of data output. This, along with an appreciable
reduction in costs, makes sequencing an increasingly realistic
option for molecular diagnosis. Emerging technologies and
existing commercial platforms have been comprehensively
reviewed and their performances compared [80,81]. High-
throughput sequencing of the 16S ribosomal RNA gene has
been enthusiastically adopted by the research community for
analysing polymicrobial populations, including those found in
the CF airways [14,20,22,24]. A recent performance comparison
of the high-throughput benchtop sequencers 454 GS Junior
(Roche), MiSeq (Illumina) and Ion Torrent PGM (Life
Technologies) reported run times ranging from 3 h to N27 h,
generating data outputs of 70–300 Mb/run [81]. Although
research studies have demonstrated the considerable potential of
next-generation sequencing, data management and processing
currently present significant bottlenecks. Following run comple-
tion, subsequent bioinformatic analysis of the output data
requires significant time and expertise which would not be
routinely available in a clinical laboratory setting. Additionally,
the discriminatory power of 16S rRNA gene sequencing is not
always sufficient for identification of bacteria to the species level,
yet this information may be required for effective clinical
treatment, for example identification of Bcc or Mycobacterium
spp [82]. Furthermore, the migration of sequencing into clinical
practice would involve an extra degree of data interrogation.
Metagenomic sequencing provides a comprehensive shotgun
view of individual microbial communities, but interpretation of
the biological data to determine clinical relevance is highly
complex requiring expert judgement. Therefore, in order to fullyRetrosp
& prospe
performa
evaluatio
Assay 
development
& proof-of-
principle
Selection of 
pathogen & 
gene targets
Fig. 1. Outline of the developmental process for a molecularealise the potential of this technology for pathogen identification
in polymicrobial infections, schemes for translating large-scale
data output into a clinically useful report need to be developed. In
particular, as mentioned previously, the clinical relevance of each
species would have to be determined including a quantitative
threshold indicating treatment and possible species interactions
likely to increase pathogenicity.
The molecular diagnosis of infections using mass spectrom-
etry incorporates a multiplex PCR/RT-PCR step for target
amplification. This is followed by mass spectrometry analysis
of the amplicons to identify which microbe targets were present
in the sample. Current examples are Abbott's PLEX-IDTM and
Agilent's MassCode PCR systems. Recently, Abbott received
CE marking for use of PLEX-IDTM with three diagnostic assays
intended for viral and bacterial identification: PLEX-ID Viral IC
Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu [83].
The PLEX-IDTM system works by determining the mass of each
PCR amplicon and then using software to calculate the nucleotide
composition of the sequence through reference to the known
molecular masses of the four nucleotides. Identification is by
comparison with a database of reference sequences. The
MassCode system uses PCR primers labelled with unique
MassTags which are distinguishable by their molecular weight
and can be cleaved from the primer by UV irradiation. Following
target amplification, unincorporated primers are removed and the
MassTags are retrieved from their amplicons for analysis bymass
spectrometry to identify which targets had been amplified.
MassCode technology has demonstrated the potential for
detection of viruses and bacteria in respiratory samples [84], but
is at present restricted to research applications.
6. Conclusions
Current CF diagnostic microbiology relies on culture-
dependent methods for the detection and identification of
microbes associated with CF airways infection. This significantly
delays results delivery and biases diagnosis towards the most
numerous and easily cultured microbes, which may not
necessarily be responsible for poor patient health. Such an
approach also requires highly specialised microbiological
expertise and judgement, leading to inconsistencies between
individuals or laboratories. Thus, culture-independent molecular
diagnostics for the direct detection of multiple infectious agents
in sputum presents an attractive prospect for improving CF
patient care.
Transition from traditional culture-dependent methods to
molecular methods would require the benefits incurred to
outweigh any disadvantages. The most likely criticism of
molecular assays is that lack of culture prevents immediateMarketing 
& uptake
Regulatory 
approval
ective
ctive 
nce 
ns
r diagnostic test from assay design to implementation.
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antibiotic susceptibility testing or strain genotyping for the
identification of epidemic clones of P. aeruginosa or Bcc.
However, it could be argued that the usefulness of current in vitro
antibiotic susceptibility tests in predicting clinical response is
questionable and that the potential of molecular methods for
predicting susceptibilities has not yet been thoroughly explored.
Moreover, in cases where strain typing of a cultured isolate is
indicated, rapid molecular testing would allow for subsequent
follow-up culture with minimal time loss.
As yet no molecular tests suitable for comprehensive CF
microbiology are commercially available, although potentially
suitable technologies and instrumentation already exist. Thus,
assay development and validation would have to be undertak-
en. The process involved in bringing a molecular assay through
from design to deployment is outlined in Fig. 1, with regulatory
approval such as CE marking and FDA approval essential for
marketing as an in vitro diagnostic for clinical use. For a
complex assay this process would take time. However, the
success of other multiplexed molecular assays for infectious
disease diagnosis demonstrates the considerable potential of a
future CF assay for rapid, robust testing in automatable formats
with a range of throughput levels. If judiciously applied to
diagnostic CF sputum microbiology in a cost-effective manner,
molecular technologies may in future help circumvent the
bottle-neck and bias associated with conventional culture and
improve detection of clinically relevant pathogens.
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